BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors

SAN JOSE, Calif., June 28, 2024 /PRNewswire/ — BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional “hard-to-drug” targets, announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks